Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 14.31% is 44% below its 2-year average of 25.60%, near the low end of its 2-year range (2.32%–123.60%).
As of the fiscal period ended Tuesday, March 31, 2026. 68.51% below its 12-month average of 45.46%.
Reported quarterly debt to assets ratio; no daily interpolation. Q3 FY2025 (2026-03-31): 14.31%.
DEBT TO ASSETS RATIO
14.31%
DEBT TO ASSETS RATIO AVG TTM
45.46%
DEBT TO ASSETS RATIO AVG 3Y
N/A
DEBT TO ASSETS RATIO AVG 5Y
N/A
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-68.51%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.10%
median of 592 covered companies
CURRENT VS SECTOR MEDIAN
+14213.28%
vs the sector median at left
Lunai Bioworks Inc.
Market Cap
$5.37M
Debt to Assets Ratio
14.31%
TTM Avg
45.46%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.31M
Debt to Assets Ratio
0.49%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.27M
Debt to Assets Ratio
0.15%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.20M
Debt to Assets Ratio
0.42%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.55M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.87M
Debt to Assets Ratio
0.25%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lunai Bioworks Inc. (LNAI) | $5.37M | 14.31% | 45.46% | N/A | N/A |
| Alzamend Neuro Inc (ALZN)vs › | $5.34M | 0.00% | N/A | N/A | N/A |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.31M | 0.49% | N/A | N/A | N/A |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.27M | 0.15% | N/A | N/A | N/A |
| Imunon, Inc. (IMNN)vs › | $5.21M | 0.52% | N/A | N/A | N/A |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs › | $5.20M | 0.42% | N/A | N/A | N/A |
| Acurx Pharmaceuticals, Inc. (ACXP)vs › | $5.55M | 0.00% | N/A | N/A | N/A |
| Lucyd, Inc (LUCY)vs › | $5.84M | 0.01% | N/A | N/A | N/A |
| Gelteq Limited Ordinary Shares (GELS)vs › | $4.87M | 0.25% | N/A | N/A | N/A |
| Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)vs › | $5.87M | 0.06% | N/A | N/A | N/A |
Debt/Assets
14.3%
Debt/Equity
N/A
Current Ratio
0.19
Interest Coverage
-25.6x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-03-31 | 14.31% |
| 2025-12-31 | 44.51% |
| 2025-09-30 | 38.89% |
| 2025-06-30 | 123.60% |
| 2025-03-31 | 5.97% |
| 2024-12-31 | 5.72% |
| 2024-09-30 | 3.14% |
| 2024-06-30 | 2.32% |
| 2024-03-31 | 4.81% |
| 2023-12-31 | 12.74% |
